Compare IMCR & UMH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMCR | UMH |
|---|---|---|
| Founded | 2008 | 1968 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.4B |
| IPO Year | 2016 | N/A |
| Metric | IMCR | UMH |
|---|---|---|
| Price | $29.80 | $14.46 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 4 |
| Target Price | ★ $61.82 | $17.75 |
| AVG Volume (30 Days) | 338.3K | ★ 447.0K |
| Earning Date | 05-06-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 6.36% |
| EPS Growth | ★ 30.39 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $249,428,000.00 | N/A |
| Revenue This Year | $14.39 | $5.62 |
| Revenue Next Year | $8.19 | $2.51 |
| P/E Ratio | ★ N/A | $203.74 |
| Revenue Growth | ★ 43.05 | N/A |
| 52 Week Low | $23.15 | $13.93 |
| 52 Week High | $40.71 | $19.02 |
| Indicator | IMCR | UMH |
|---|---|---|
| Relative Strength Index (RSI) | 36.39 | 34.65 |
| Support Level | N/A | $14.01 |
| Resistance Level | $34.35 | $14.95 |
| Average True Range (ATR) | 1.28 | 0.28 |
| MACD | -0.20 | -0.03 |
| Stochastic Oscillator | 12.16 | 45.08 |
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
UMH Properties Inc together with its subsidiaries is a real estate investment trust. It is engaged in the business of ownership and operation of manufactured home communities - leasing manufactured homesites to residents . The Company also leases manufactured homes to residents and, through its wholly-owned taxable REIT subsidiary, UMH Sales and Finance, Inc. sells and finances the sale of manufactured homes to residents and prospective residents of its communities and for placement on customers' privately-owned land. The company also owns the land, utility connections, streets, lighting, driveways, common area amenities, and other capital improvements. It earns income from lease agreements for their sites and homes, where the company is the lessor.